NUMA1 and cancer: We investigated whether a new, noninvasive urine-based test for the nuclear matrix, protein NMP22 proteomic marker, using monoclonal antibodies in a point of care format, has clinical utility as an aid in diagnosis of bladder cancer and compared its ability to detect cancer with that of voided urine cytology.